{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:51:53Z","timestamp":1790110313535,"version":"4.0.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anaemia is common in chronic kidney disease (CKD) and assessment of the risks and benefits of new therapies is important.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Anaemia Study in CKD: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) trial includes adult patients with CKD Stages 3\u20135, not using erythropoiesis-stimulating agents (ESAs) with screening haemoglobin (Hb) 8\u201310\u00a0g\/dL or receiving ESAs with screening Hb of 8\u201312\u00a0g\/dL. Participants were randomized to daprodustat or darbepoetin alfa (1:1) in an open-label trial (steering committee- and sponsor-blinded), with blinded endpoint assessment. The co-primary endpoints are mean change in Hb between baseline and evaluation period (average over Weeks 28\u201352) and time to first adjudicated major adverse cardiovascular (CV) event. Baseline characteristics were compared with those of participants in similar anaemia trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 3872 patients were randomized from 39\u00a0countries (median age 67 years, 56% female, 56% White, 27% Asian and 10% Black). The median baseline Hb was 9.9\u00a0g\/dL, blood pressure was 135\/74\u00a0mmHg and estimated glomerular filtration rate was 18\u00a0mL\/min\/1.73 m2. Among randomized patients, 53% were ESA non-users, 57% had diabetes and 37% had a history of CV disease. At baseline, 61% of participants were using renin\u2013angiotensin system blockers, 55% were taking statins and 49% were taking oral iron. Baseline demographics were similar to those in other large non-dialysis anaemia trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>ASCEND-ND will define the efficacy and safety of daprodustat compared with darbepoetin alfa in the treatment of patients with anaemia associated with CKD not on dialysis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfab318","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T20:53:35Z","timestamp":1637700815000},"page":"2157-2170","source":"Crossref","is-referenced-by-count":13,"title":["The ASCEND-ND trial: study design and participant characteristics"],"prefix":"10.1093","volume":"37","author":[{"given":"Vlado","family":"Perkovic","sequence":"first","affiliation":[{"name":"University of New South Wales , Sydney , NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Blackorby","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Collegeville , PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borut","family":"Cizman","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Collegeville , PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Carroll","sequence":"additional","affiliation":[{"name":"KJC Statistics , Cheshire , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R","family":"Cobitz","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Collegeville , PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich","family":"Davies","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Collegeville , PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara L","family":"DiMino","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Collegeville , PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Jha","sequence":"additional","affiliation":[{"name":"George Institute for Global Health , New Delhi , India"},{"name":"Faculty of Medicine , Imperial College, London , UK"},{"name":"Manipal Academy of Higher Education , Manipal , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten L","family":"Johansen","sequence":"additional","affiliation":[{"name":"Hennepin Healthcare, University of Minnesota , Minneapolis, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lata","family":"Kler","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Collegeville , PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9804-0657","authenticated-orcid":false,"given":"Iain C","family":"Macdougall","sequence":"additional","affiliation":[{"name":"King's College Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, Scotland , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M","family":"Meadowcroft","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Collegeville , PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio T","family":"Obrador","sequence":"additional","affiliation":[{"name":"Universidad Panamericana School of Medicine , Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Taft","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , Collegeville , PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut S","family":"Waikar","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine and Boston Medical Center , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[{"name":"Medical University of Silesia , Katowice , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K","family":"Singh","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"2022102109180932300_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1525-139X.2007.00329.x","article-title":"The optimal hemoglobin in dialysis patients: a critical review","volume":"21","author":"Singh","year":"2008","journal-title":"Semin Dial"},{"key":"2022102109180932300_bib2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/j.jrn.2019.11.003","article-title":"Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3\u20135 nondialysis CKD","volume":"30","author":"Hoshino","year":"2020","journal-title":"J Ren Nutr"},{"key":"2022102109180932300_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfg458","article-title":"Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2022102109180932300_bib4","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes Anemia Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2022102109180932300_bib5","article-title":"Chronic kidney disease: managing anaemia","author":"National Institute for Health and Care Excellence"},{"key":"2022102109180932300_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nep.12148","article-title":"Cardiovascular disease in patients with chronic kidney disease","volume":"19","author":"Pilmore","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"2022102109180932300_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"2022102109180932300_bib8","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"2022102109180932300_bib9","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"2022102109180932300_bib10","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102109180932300_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"2022102109180932300_bib12","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"2022102109180932300_bib13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.04601007","article-title":"Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients","volume":"3","author":"Kilpatrick","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102109180932300_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/MNH.0000000000000554","article-title":"Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease","volume":"28","author":"McMahon","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2022102109180932300_bib15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102109180932300_bib16","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/ndt\/gfaa204","article-title":"Global phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials","volume":"36","author":"Eckardt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2022102109180932300_bib17","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"},{"key":"2022102109180932300_bib18","article-title":"Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial","author":"Singh","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2022102109180932300_bib19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2022102109180932300_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2020.10.068","article-title":"Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics","volume":"235","author":"Chertow","year":"2021","journal-title":"Am Heart J"},{"key":"2022102109180932300_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2009.04.008","article-title":"Baseline characteristics in the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)","volume":"54","author":"Pfeffer","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2022102109180932300_bib22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/1744-9987.12962","article-title":"A 24-week anemia correction study of daprodustat in Japanese dialysis patients","volume":"24","author":"Tsubakihara","year":"2020","journal-title":"Ther Apher Dial"},{"key":"2022102109180932300_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/08037059209077502","article-title":"Prospective Randomized Open Blinded End-point (PROBE) study. A novel design for intervention trials","volume":"1","author":"Hansson","year":"1992","journal-title":"Blood Press"},{"key":"2022102109180932300_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ckj\/sfy013","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease","volume":"12","author":"Holdstock","year":"2019","journal-title":"Clin Kidney J"},{"key":"2022102109180932300_bib25","author":"Amgen"},{"key":"2022102109180932300_bib26","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102109180932300_bib27","volume-title":"FibroGen provides additional information on Roxadustat","author":"FibroGen"},{"key":"2022102109180932300_bib28","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2022102109180932300_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24- week, open-label, randomized controlled trial in participants on hemodialysis","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clin Kidney J"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfab318\/42880669\/gfab318.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/11\/2157\/46586000\/gfab318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/11\/2157\/46586000\/gfab318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T09:22:26Z","timestamp":1666344146000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/11\/2157\/6448498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,12,2]]},"published-print":{"date-parts":[[2022,10,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfab318","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11]]},"published":{"date-parts":[[2021,12,2]]}}}